CVSI | Ticker Profile - Titan Protect

CVSI

CV Sciences, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · OQB

$0.03

Data: 2026-05-13

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6M

Total market value of the company

Trailing P/E

0.00

Forward P/E

-0.74

Based on estimated future earnings — lower means cheaper

Rev Growth

-14.9%

Year-over-year revenue change

Profit Margin

-6.9%

How much profit the company keeps from each dollar of revenue

ROE

-58.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About CV Sciences, Inc.

CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

https://www.cvsciences.com

Country: United States Employees: 42 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

35.0% FAIL

Debt must be below 33% of total assets

Cash Ratio

4.9% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.778

Good returns relative to risk taken

Kelly Fraction

-0.5330

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.369

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-29.5%

Historical annualised return based on price data

Max Drawdown

-80.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.45

Very low correlation to market moves

52W High

$0.10

70% below the year high

52W Low

$0.02

50% above the year low

Avg Volume

1,247,619

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.01

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.36

Meaningful debt load — monitor closely

Current Ratio

1.03

Adequate but worth monitoring

Quick Ratio

0.14

Like current ratio but excludes inventory — stricter test

Gross Margin

49.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2.3%

Profit from core operations before interest and tax

Free Cash Flow

$-209,875

Negative — the business is spending more than it generates

Revenue (TTM)

$14M

Total revenue over the last 12 months

Net Income

$-958,000

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Before you go